Services

The partner organisations within the Agora Consulting network have extensive expertise in advising client companies on the pharmaceutical, biotech and medical device sectors in their respective countries. The combined expertise that exists within Agora Consulting can assist you to successfully penetrate key European healthcare markets and to decide on the appropriate channels of distribution.

The Agora Consulting network has particular expertise in advising client companies on obtaining reimbursement for:

  • Medical devices
  • Pharmaceutical products
  • Biotech

Additionally, our expertise in relation to pricing strategies can help ensure the optimum return for your company's products.

The strength of Agora Consulting is not just the expertise in individual country markets but also the combined expertise of the network; this is particularly advantageous to companies considering the introduction of pharmaceutical and medical device products in multiple European markets.

Make Agora Consulting your preferred consultancy partner of choice to successfully enter the pharmaceutical and medical device markets throughout Europe.

Agora Consulting’s mission is to provide expert advice and consultancy services on market access and reimbursement in the European healthcare market.

Your requirements How Agora Consulting can help
Market/regulatory data
  • Identify key players
  • Market size data
  • Highlight funding flows
  • Profile regulatory environment
Market access
  • Provide data on:
    • Diagnostic Related Groups
    • Health Technology Assessments
  • Develop market access strategies
Reimbursement
  • Prepare reimbursement road-map
  • Information on payment rates
  • Data on innovative products
  • Provision of specialised advice
Pricing
  • Reimbursement applications
  • Global value dossiers
  • Negotiation support
Marketing/sales (US)
  • Recruitment of sales teams
  • Marketing communications
  • Publishing

KEY FACTS

UK: The National Health Service (NHS) is offering suppliers of products and services involved in the treatment of heart diseases, cancer and other long-term conditions an opportunity to have them evaluated in a clinical setting. For further details on the Smart Solutions for Healthcare programme, see (.../)


GERMANY: The Federal Ministry of Health has decided to increase the contribution of sick funds from 14.9 per cent to 15.5 per cent. What’s bad news for consumers represents a ray of hope for providers of medical products and services. More information on this fund which is compensated by the national budget to the tune of 15.7 billion Euro can be found here (.../)